Modified FOLFOX6
Modified FOLFOX6 is a pharmaceutical drug with 10 clinical trials. Historical success rate of 77.8%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
6
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
70.0%
7 of 10 finished
30.0%
3 ended early
0
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
Clinical Trials (10)
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
Molecularly Tailored Therapy for Pancreas Cancer
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10